Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Not Yet Opened 12-31 16:00:00 EST

1.58

-0.28

-15.28%

盘后0.5800

-1.00-63.29%

19:59 EST

High1.83	Low1.52	Vol34.09M
Open1.62	D1 Closing1.87	Amplitude16.62%
Mkt Cap101.30M	Tradable Cap77.07M	Total Shares64.11M
T/O56.02M	T/O Rate69.88%	Tradable Shares48.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":1.58,"timestamp":1767214800000,"preClose":1.865,"halted":0,"volume":34085570,"hourTrading":{"tag":"盘后","latestPrice":0.58,"preClose":1.58,"latestTime":"19:59 EST","volume":20367941,"amount":9607899.22421,"timestamp":1767229199355},"delay":0,"floatShares":48780400,"shares":64114399,"eps":-1.794017,"marketStatus":"Not Yet Opened","change":-0.285,"latestTime":"12-31 16:00:00 EST","open":1.62,"high":1.83,"low":1.52,"amount":56023175.785723,"amplitude":0.16622,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.794017,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1767344400000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.865,"preHourTrading":{"tag":"盘前","latestPrice":1.591,"preClose":1.865,"latestTime":"09:29 EST","volume":1990567,"amount":3245634.0246391003,"timestamp":1767191397564},"postHourTrading":{"tag":"盘后","latestPrice":0.58,"preClose":1.58,"latestTime":"19:59 EST","volume":20367941,"amount":9607899.22421,"timestamp":1767229199355},"volumeRatio":7.617765874771373,"impliedVol":3.1294,"impliedVolPercentile":0.828},"requestUrl":"/m/hq/s/OTLK","defaultTab":"news","newsList":[{"id":"2600870287","title":"Stocks to Watch: Nuvve, Outlook Therapeutics, Rubico","url":"https://stock-news.laohu8.com/highlight/detail?id=2600870287","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600870287?lang=en_us&edition=fundamental","pubTime":"2026-01-01 06:51","pubTimestamp":1767221460,"startTime":"0","endTime":"0","summary":"Nuvve closed a private placement with gross proceeds of $5.4 million. Shares fell 14% to $2.18 in after-hours trading Wednesday.Outlook Therapeutics said the Food and Drug Administration rejected its application for a treatment of macular degeneration. The stock slid 69% to 49 cents after the bell.Rubico agreed to buy a vessel-owning company. Shares climbed 29% to $1.38.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","RUBI","OTLK","BK4096","BK4139","BK4539","LENZ","BK4007","NVVE"],"gpt_icon":0},{"id":"2600704733","title":"BRIEF-Outlook Therapeutics Provides Regulatory Update On U.S. FDA Review Of Lytenava","url":"https://stock-news.laohu8.com/highlight/detail?id=2600704733","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600704733?lang=en_us&edition=fundamental","pubTime":"2026-01-01 06:36","pubTimestamp":1767220587,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Provides Regulatory Update On U.S. FDA Review Of Lytenava Dec 31 (Reuters) - Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS PROVIDES REGULATORY UPDATE ON U.S. FOOD AND","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nTUABSFNFS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2600704580","title":"Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2600704580","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600704580?lang=en_us&edition=fundamental","pubTime":"2026-01-01 06:05","pubTimestamp":1767218700,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration.The stock dropped 71% to 45 cents a share in after-hours trading. Through the close, shares had lost 16% this year.The Iselin, N.J., biopharmaceutical company said Wednesday it received notice that the FDA wouldn't approve its biologics license application for ONS-5010/Lytenava, which is designed to treat wet age-related macular degeneration.Outlook said the FDA was requesting more confirmatory evidence of the drug's efficacy, though it didn't provide details on what kind of evidence it was looking for.In August, the FDA said it wouldn't approve the drug for similar reasons. Also, in 2023, the FDA turned away Outlook's initial application for ONS-5010, saying it had issues with chemistry, manufacturing and controls.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK","LENZ","BK4539","BK4007"],"gpt_icon":0},{"id":"2600701922","title":"Outlook Therapeutics Says FDA Issued Complete Response Letter to ONS-5010 BLA Resubmission","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701922","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701922?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:33","pubTimestamp":1767216792,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics  said Wednesday the US Food and Drug Administration has issued a complete response letter to the ONS-5010 biologics license application resubmission.The move indicates the regulator cannot approve the application in its present form for the treatment of wet age-related macular degeneration, the company said.Outlook Therapeutics said it is exploring \"all available pathways\" for potential clearance in the US and it also plans to continue its efforts to expand into more markets in Europe and other regions.Trading in shares of Outlook Therapeutics were halted.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OTLK","BK4539","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2600701342","title":"US FDA declines to approve Outlook Therapeutics' eye disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701342","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701342?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:19","pubTimestamp":1767215956,"startTime":"0","endTime":"0","summary":"US FDA declines to approve Outlook Therapeutics' eye disease drugDec 31  - The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' drug for a type of eye disease, the company said on Wednesday, marking another setback to its prolonged effort to bring the treatment to market.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nL4N3Y10VF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2600701334","title":"Outlook Therapeutics Inc - FDA Issues Complete Response Letter for Ons-5010 Bla","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701334?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:15","pubTimestamp":1767215700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nTUABSFNFS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2600370135","title":"Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™ (Bevacizumab-Vikg) for the Treatment of Wet Amd","url":"https://stock-news.laohu8.com/highlight/detail?id=2600370135","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600370135?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:15","pubTimestamp":1767215700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nTUABSFNFS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2600332701","title":"Outlook Therapeutics Inc:  Currently Exploring All Available Pathways for Potential Approval in U.s","url":"https://stock-news.laohu8.com/highlight/detail?id=2600332701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600332701?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:15","pubTimestamp":1767215700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nTUABSFNFS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2600013597","title":"Outlook Therapeutics Inc: FDA Has Not Indicated What Type of Confirmatory Evidence Would Be Acceptable","url":"https://stock-news.laohu8.com/highlight/detail?id=2600013597","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600013597?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:15","pubTimestamp":1767215700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nTUABSFNFS:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2600701899","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:10 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701899","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701899?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:10","pubTimestamp":1767215400,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:10 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nAQN2LFYHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2594564215","title":"Outlook Therapeutics Grants Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2594564215","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594564215?lang=en_us&edition=fundamental","pubTime":"2025-12-27 06:00","pubTimestamp":1766786409,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc. has granted stock options to purchase a total of 150,000 shares of its common stock at an exercise price of $2.01 per share to two new employees, effective December 19, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251226:nNDL25sSdf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","BK4588","OTLK","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","BK4585","SG9999014021.USD","BK4139","SG9999014039.USD","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2592162529","title":"BRIEF-Outlook Therapeutics FY EPS USD -1.79","url":"https://stock-news.laohu8.com/highlight/detail?id=2592162529","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592162529?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:05","pubTimestamp":1766149545,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics FY EPS USD -1.79\n\n\nDec 19 (Reuters) - Outlook Therapeutics FY net income USD -62.4 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nPLX192CCB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2592625211","title":"Outlook Therapeutics FY2025 net loss narrows to USD 62.4 million, revenue reaches USD 1.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2592625211","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592625211?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:05","pubTimestamp":1766149517,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc. reported financial results for the full year ended September 30, 2025. The company recorded revenue of USD 1.4 million for the period. Net loss attributable to common stockholders was USD 62.4 million, or USD 1.79 per basic and diluted share. As of September 30, 2025, cash and cash equivalents stood at USD 8.1 million. Gross profit for the year was negatively affected by increased reserves for short-dated inventory included in original shipments to the UK in June 2025. Overall expenses for the fiscal year were USD 4.6 million lower than the previous year, primarily due to a reduction in research and development expenses following the completion of the NORSE Eight clinical trial in fiscal 2024. This decrease was partially offset by higher selling, general, and administrative expenses related to the launch of LYTENAVA in Europe in June 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLc4fhc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2095319765.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014021.USD","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","OTLK","BK4112","NDAQ","BK4585","BK4139","SG9999014005.SGD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2592162582","title":"Outlook Therapeutics FY Net Income USD -62.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2592162582","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592162582?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:05","pubTimestamp":1766149500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nPLX192CCB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2592617162","title":"Press Release: Outlook Therapeutics Reports Financial Results for Fiscal Year 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2592617162","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592617162?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:05","pubTimestamp":1766149500,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., Dec. 19, 2025  -- Outlook Therapeutics, Inc. , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for fiscal year 2025.\"Over the course of fiscal year 2025, our team has worked diligently to position Outlook Therapeutics for success. We are preparing now for potential approval and progressing commercial launch activities in the U.S., as we await a decision from the FDA in just a few short weeks,\" commented Bob Jahr, Chief Executive Officer of Outlook Therapeutics. \"In Europe, our initial shipments of inventory are being used to prime and prepare to grow the market. Commercial activities remain ongoing as we push ahead with our efforts to expand into the next wave of country launches, including Austria and the Netherlands. Outside the U.S., we continue to identify potential partners for additional expansion. As we","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","IE00BMPRXR70.SGD","LU1861558580.USD","BK4139","LU1803068979.SGD","IE0009356076.USD","LU1852331112.SGD","LU2098885051.SGD","LU2250418816.HKD","BK4539","BK4555","BK4588","LU0823434740.USD","LU1880398554.USD","LU0127658192.USD","LU2931357623.SGD","IE0004445239.USD","BK4512","LU0889565833.HKD","LU1951198990.SGD","BK4532","BK4141","BK4554","LU0109392836.USD","LU0642271901.SGD","LU0056508442.USD","LU2355687059.USD","LU2264538146.SGD","BK4099","LU0082616367.USD","LU1242518857.USD","LU2458330243.SGD","LU0823421333.USD","LU0390134368.USD","LU1064131342.USD","03160","BK4543","BK4529","BK4573","BK4605","LU1242518931.SGD","LU1923623000.USD","LU1988902786.USD","LU2360106780.USD","BK4604","LU1880398471.USD","LU2089985449.USD","LU0081259029.USD","LU1316542783.SGD","LU1989764664.SGD","LU1861559042.SGD","BK4566","BK4575","BK4612","LU0823421416.USD","BK4007","LU0823434583.USD","LU2458330169.SGD","BK4614","LU2054465674.USD","LU0274383776.USD","LU0198837287.USD","LU0719512351.SGD","LU1303367103.USD","LU1951200564.SGD","LU0979878070.USD","IE00B5949003.HKD","IE00BMPRXN33.USD","BK4534","BK4585"],"gpt_icon":0},{"id":"2592969977","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2592969977","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592969977?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:00","pubTimestamp":1766055600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.FactSet Research Syss Inc.                       1Q      4.36   6:00 AM. Innovative Solutions and Support Inc.           4Q       .11       BMO. NIKE Inc. Class B                                2Q       .37   4:15 PM. Lamb Weston Hldgs Inc.                            2Q       .64   8:30 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1228905037.USD","LU2506952097.USD","LW","BK4112","BIRK","LU0310800965.SGD","PAYX","IE00BYQQ9H92.USD","LU1989772923.USD","KMX","HEI.A","LU0545039389.USD","FDX","BK4561","OTLK","FCEL","BK4212","LU2506951958.HKD","BK4547","HEI","BK4524","BK4146","BK4566","DRI","NNE","DRUG","WGO","BK4534","IE00BJJMRY28.SGD","LU0154245756.USD","BK4588","IE00BFXG0V08.USD","IE00BVYPNV92.GBP","CUK","LU0823417653.USD","LU2506951875.HKD","LU1823568750.SGD","LU0052756011.USD","LU0786609619.USD","CAG","LU0823417737.USD","CTAS","KBH","ACN","LU1366333091.USD","NKE","FDS","LU0868494708.USD","ISSC"],"gpt_icon":1},{"id":"2591648985","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648985","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591648985?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:00","pubTimestamp":1765796400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Enerpac Tool Grp Corp Class A                   1Q       .37       AMC. FactSet Research Syss Inc.                       1Q      4.36   6:00 AM. Innovative Solutions and Support Inc.           4Q       .11       BMO. NIKE Inc. Class B                                2Q       .38   4:15 PM. Lamb Weston Hldgs Inc.                            2Q       .64   8:30 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDX","OGI","WGO","GIS","TTC","BK4209","BK4131","HEI","AMC","CTAS","DRUG","LU0950375773.USD","LW","HEI.A","LEN.B","KMX","JBL","LU1046421795.USD","ABM","ISSC","VERU","MU","SG9999004303.SGD","DRI","NAVN","PAYX","LU0056508442.USD","BIRK","MLKN","BK4553","FCEL","BK4130","EPAC","FDS","BK4567","ACN","OTLK","IE00BSNM7G36.USD","BK4152","CUK","LU0323240290.USD","NKE","IE00BJJMRX11.SGD","LEN","CAG","LU1235294995.USD","AMCDD","KBH","LEN/WD","WOR"],"gpt_icon":1},{"id":"2583680037","title":"H.C. Wainwright Sticks to Its Hold Rating for Outlook Therapeutics (OTLK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583680037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583680037?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:39","pubTimestamp":1763163566,"startTime":"0","endTime":"0","summary":"In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on Outlook Therapeutics, with a price target of $1.00. Accor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-hold-rating-for-outlook-therapeutics-otlk-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-hold-rating-for-outlook-therapeutics-otlk-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OTLK"],"gpt_icon":0},{"id":"2583593112","title":"Outlook Therapeutics announces acceptance of BLA for ONS-5010","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593112","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593112?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:35","pubTimestamp":1763040944,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced that the U.S. Food and Drug Administration, FDA, has acknowledged receipt of the resubmission of the Biologic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-announces-acceptance-of-bla-for-ons-5010-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-announces-acceptance-of-bla-for-ons-5010-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","OTLK","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2583593378","title":"Outlook Therapeutics Inc - FDA Sets Pdufa Goal Date of December 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593378?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5XQJTH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1366},{"period":"1month","weight":-0.1505},{"period":"3month","weight":0.4766},{"period":"6month","weight":-0.1124},{"period":"1year","weight":-0.164},{"period":"ytd","weight":-0.164}],"compareEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.019},{"period":"6month","weight":0.0905},{"period":"1year","weight":0.1635},{"period":"ytd","weight":0.1635}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.117155},{"month":2,"riseRate":0.444444,"avgChangeRate":0.160578},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.049534},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.10242},{"month":5,"riseRate":0.666667,"avgChangeRate":0.154179},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.046947},{"month":7,"riseRate":0.6,"avgChangeRate":0.042124},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction